Paul Coppo

15.1k total citations · 3 hit papers
248 papers, 7.9k citations indexed

About

Paul Coppo is a scholar working on Immunology, Hematology and Nephrology. According to data from OpenAlex, Paul Coppo has authored 248 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 211 papers in Immunology, 121 papers in Hematology and 94 papers in Nephrology. Recurrent topics in Paul Coppo's work include Complement system in diseases (177 papers), Renal Diseases and Glomerulopathies (94 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (67 papers). Paul Coppo is often cited by papers focused on Complement system in diseases (177 papers), Renal Diseases and Glomerulopathies (94 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (67 papers). Paul Coppo collaborates with scholars based in France, United States and Belgium. Paul Coppo's co-authors include Lionel Galicier, Agnès Veyradier, Bérangère S. Joly, Olivier Lambotte, L. Fardet, Christophe Marzac, Agnès Veyradier, Cédric Aumont, Johanna A. Kremer Hovinga and Gilles Hejblum and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paul Coppo

223 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome

2014 868 citations Olivier Lambotte, Paul Coppo et al. profile →
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

2019 602 citations Marie Scully, Spero R. Cataland et al. profile →
Thrombotic thrombocytopenic purpura

2017 414 citations Bérangère S. Joly, Paul Coppo et al. Blood profile →

Peers

Countries citing papers authored by Paul Coppo

Since Specialization

Citations

This map shows the geographic impact of Paul Coppo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Coppo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Coppo more than expected).

Fields of papers citing papers by Paul Coppo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Coppo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Coppo. The network helps show where Paul Coppo may publish in the future.

Co-authorship network of co-authors of Paul Coppo

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Coppo. A scholar is included among the top collaborators of Paul Coppo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Coppo. Paul Coppo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP 2025 ·Blood Advances ·(unknown), (unknown), (unknown), (unknown), Paul Kaijen, Paul Coppo, Bérangère S. Joly, Agnès Veyradier, Karen Vanhoorelbeke, Jan Voorberg	0
2	Splenectomy allows remission of angioedema with acquired C1-inhibitor deficiency associated with splenic marginal zone lymphoma 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Simon Valayer, Federica Defendi, Carine El Sissy, Damien Roos‐Weil, Félix Ackermann, Laurence Bouillet, Isabelle Boccon‐Gibod, Paul Coppo, Najim Chafaı̈, (unknown), Chloé McAvoy, O. Fain, Delphine Gobert	0
3	Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation 2024 ·Journal of Thrombosis and Haemostasis ·(unknown), (unknown), (unknown), Edwige Tellier, Gilles Kaplanski, Bérangère S. Joly, Agnès Veyradier, Paul Coppo, Jeroen Lammertyn, Claudia Tersteeg, Simon F. De Meyer, Karen Vanhoorelbeke	3
4	Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes 2024 ·Nephrology Dialysis Transplantation ·Adrien Joseph, Stéphanie Harel, Laurent Mesnard, Cédric Rafat, (unknown), (unknown), Carole Philipponnet, (unknown), Jean-Michel Rebibou, David Buob, Alexandre Hertig, Jacques Vargaftig, Jean‐Michel Halimi, Bertrand Arnulf, (unknown), Bérangère S. Joly, Steven Grangé, Paul Coppo	4
5	Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience 2023 ·Blood Advances ·(unknown), Paul Coppo, Vassilis Tsatsaris, Pierre Boisseau, François Provôt, Yahsou Delmas, Pascale Poullin, Karen Vanhoorelbeke, Agnès Veyradier, Bérangère S. Joly	7
6	The challenging follow-up of pregnancy in women with known thrombotic thrombocytopenic purpura: a single-center experience of a preemptive management protocol 2023 ·Journal of Nephrology ·Aghilès Hamroun, (unknown), (unknown), (unknown), Anne Bauters, Christophe Zawadzki, D. Subtil, Jean‐Baptiste Gibier, (unknown), Paul Coppo, Arnaud Lionet, Mehdi Maanaoui, Marc Hazzan, François Provôt	1
7	Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease 2023 ·British Journal of Haematology ·(unknown), (unknown), Olivier Lambotte, Bérangère S. Joly, Paul Coppo, Nadia Anguel, Céline Labeyrie	1
8	Cytomegalovirus lymphadenitis mimicking a relapsed diffuse large B‐cell lymphoma 2022 ·SHILAP Revista de lepidopterología ·Matthieu Delaye, Laure Ricard, (unknown), Suzanne Chartier, Paul Coppo	2
9	Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study 2022 ·Journal of Thrombosis and Haemostasis ·Marie Scully, Javier de la Rubia, (unknown), Ara Metjian, Paul Knöbl, Flora Peyvandi, Spero R. Cataland, Paul Coppo, Johanna A. Kremer Hovinga, (unknown), (unknown), Filip Callewaert, Sriya Gunawardena, Julie Lin	14
10	Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis 2022 ·Journal of Clinical Medicine ·Laure Burguet, Benjamin Taton, (unknown), Sébastien Rubin, Walter Picard, Didier Gruson, (unknown), Cécile Contin‐Bordes, Paul Coppo, Christian Combe, Yahsou Delmas	6
11	TTP: From empiricism for an enigmatic disease to targeted molecular therapies 2022 ·British Journal of Haematology ·(unknown), Bérangère S. Joly, Jan Voorberg, Karen Vanhoorelbeke, (unknown), Agnès Veyradier, Paul Coppo	11
12	N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP 2021 ·Blood ·(unknown), (unknown), Kadri Kangro, (unknown), Kanin Wichapong, (unknown), Paul Kaijen, Floris P. J. van Alphen, Maartje van den Biggelaar, Karen Vanhoorelbeke, Agnès Veyradier, Paul Coppo, Chris Reutelingsperger, Gerry A. F. Nicolaes, Andres Männik, Jan Voorberg	13
13	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis 2021 ·Blood Advances ·Flora Peyvandi, Spero R. Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, (unknown), Hilde De Winter, Filip Callewaert	50
14	Redefining outcomes in immune TTP: an international working group consensus report 2021 ·Blood ·Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, (unknown), Paul Knoebl, Johanna A. Kremer Hovinga, Bernhard Lämmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, (unknown), Yoshiaki Tomiyama, Agnès Veyradier, John‐Paul Westwood, Marie Scully	121
15	Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma 2020 ·European Journal Of Haematology ·Zoé Van de Wyngaert, Paul Coppo, Pascale Cervera, Bettina Fabiani, (unknown), (unknown), Zora Marjanovic, Malek Aoudjhane, Mohamad Mohty, Rémy Duléry	10
16	Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers 2018 ·Haematologica ·(unknown), (unknown), (unknown), (unknown), Karen Vanhoorelbeke, Agnès Veyradier, Jan Voorberg, Paul Coppo	31
17	Thrombotic microangiopathies and antineoplastic agents 2017 ·Néphrologie & Thérapeutique ·Steven Grangé, Paul Coppo	16
18	Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre 2016 ·Blood ·Maximilien Grall, François Provôt, Jean‐Philippe Coindre, Claire Pouteil‐Noble, Dominique Guerrot, Y. Benhamou, Dominique Bordessoule, Agnès Veyradier, Paul Coppo, Steven Grangé	6
19	Purpura thrombotique thrombocytopénique par déficit héréditaire en ADAMTS13 (syndrome d’Upshaw-Schulman) : actualités et perspectives 2005 ·Hématologie ·Agnès Veyradier, Chantal Loirat, Jean‐Pierre Girma, Anne‐Sophie Ribba, Martine Wolf, Paul Coppo, Dominique Meyer	3
20	Conduite à tenir devant une hypogammaglobulinémie 2001 ·Kaı̈ss Lassoued, Paul Coppo	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact